{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:27:37Z","timestamp":1785414457926,"version":"3.56.0"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K18560"],"award-info":[{"award-number":["24K18560"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07204"],"award-info":[{"award-number":["21K07204"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>KRASG12C inhibitors, such as sotorasib, show clinical efficacy for non\u2013small cell lung cancer (NSCLC) positive for the G12C mutations of KRAS, but primary and acquired resistance to these drugs remains a clinical problem. In this study, we show that the development of resistance to sotorasib in KRASG12C-positive NSCLC cells was mediated by constitutive activation of EGFR resulting from downregulation of the protein tyrosine phosphatase receptor type R (PTPRR). PTPRR has been identified as a physiologic regulator of ERK signaling in several cancer types. In our study, PTPRR was demonstrated to bind directly to EGFR, facilitating its dephosphorylation on tyrosine residues. Resumption of PTPRR expression in the resistant cells attenuated EGFR phosphorylation and restored sotorasib sensitivity. PTPRR downregulation was associated with gene promoter hypermethylation in the sotorasib-resistant cells and NSCLC tissue samples. Furthermore, low PTPRR expression in tumor specimens was associated with shorter progression-free and overall survival for patients with NSCLC treated with sotorasib. In contrast to sotorasib, high PTPRR expression was associated with a poor response to EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC, suggesting that PTPRR may broadly regulate EGFR dependence in NSCLC. Finally, dual blockade of KRASG12C and EGFR showed a substantial antitumor effect in a xenograft model of sotorasib-resistant NSCLC. This approach is therefore a rational therapeutic strategy for KRASG12C-positive NSCLC, especially for tumors showing PTPRR downregulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The current study shows that downregulation of PTPRR induces EGFR activation and resistance to KRASG12C inhibitors in NSCLC, suggesting dual KRAS-EGFR blockade as a rational therapy. PTPRR may help identify patient subgroups that would benefit from the addition of EGFR inhibitors to KRASG12C-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0489","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:01:37Z","timestamp":1773205297000},"page":"728-741","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0858-8107","authenticated-orcid":false,"given":"Hiroaki","family":"Kanemura","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-2978","authenticated-orcid":false,"given":"Toshiyuki","family":"Takehara","sequence":"additional","affiliation":[{"name":"2Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6946-810X","authenticated-orcid":false,"given":"Osamu","family":"Maenishi","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-936X","authenticated-orcid":false,"given":"Shuta","family":"Tomida","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019tepx80","id-type":"ROR","asserted-by":"publisher"}],"name":"Okayama University Hospital 4 Center for Comprehensive Genomic Medicine, , Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7983-762X","authenticated-orcid":false,"given":"Natsumi","family":"Iwawaki","sequence":"additional","affiliation":[{"name":"2Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-3486","authenticated-orcid":false,"given":"Kei","family":"Kunimasa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/010srfv22","id-type":"ROR","asserted-by":"publisher"}],"name":"Osaka International Cancer Institute 5 Department of Thoracic Oncology, , Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4035-4658","authenticated-orcid":false,"given":"Tomohiro","family":"Nakayama","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jhgy173","id-type":"ROR","asserted-by":"publisher"}],"name":"Kishiwada City Hospital 6 Department of Medical Oncology, , Kishiwada, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-8721","authenticated-orcid":false,"given":"Satomi","family":"Watanabe","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01jhgy173","id-type":"ROR","asserted-by":"publisher"}],"name":"Kishiwada City Hospital 6 Department of Medical Oncology, , Kishiwada, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-2214","authenticated-orcid":false,"given":"Shinichiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2720","authenticated-orcid":false,"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[{"name":"7Department of Genome Biology, Kindai University Faculty of Medicine, Sakai, Japan."},{"name":"8Center for Genomics, Life Science Research Institute, Kindai University, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-5856","authenticated-orcid":false,"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"9Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8390-2600","authenticated-orcid":false,"given":"Keita","family":"Kudo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02k3rdd90","id-type":"ROR","asserted-by":"publisher"}],"name":"National Hospital Organization Osaka Minami Medical Center 10 Department of Medical Oncology, , Kawachinagano, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-0846","authenticated-orcid":false,"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[{"name":"7Department of Genome Biology, Kindai University Faculty of Medicine, Sakai, Japan."},{"name":"8Center for Genomics, Life Science Research Institute, Kindai University, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-9776","authenticated-orcid":false,"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-4749","authenticated-orcid":false,"given":"Takeshi","family":"Teramura","sequence":"additional","affiliation":[{"name":"2Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-5315","authenticated-orcid":false,"given":"Kimio","family":"Yonesaka","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2026040200274608600_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"2026040200274608600_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"2026040200274608600_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026040200274608600_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"2026040200274608600_bib5","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"2026040200274608600_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRASG12C somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2026040200274608600_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"2026040200274608600_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"2026040200274608600_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026040200274608600_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"key":"2026040200274608600_bib18","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026040200274608600_bib19","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"2026040200274608600_bib20","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRASG12C inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"2026040200274608600_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"2026040200274608600_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026040200274608600_bib24","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"key":"2026040200274608600_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-024-01945-9","article-title":"Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol Cancer"},{"key":"2026040200274608600_bib26","first-page":"15933","article-title":"Yes associated protein is a poor prognostic factor in well-differentiated lung adenocarcinoma","volume":"8","author":"Kim","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2026040200274608600_bib27","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-21-0856","article-title":"KRAS inhibitor resistance in MET-amplified KRASG12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026040200274608600_bib28","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1093\/emboj\/17.24.7337","article-title":"PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif","volume":"17","author":"Pulido","year":"1998","journal-title":"EMBO J"},{"key":"2026040200274608600_bib29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1476-4598-8-124","article-title":"The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis","volume":"8","author":"Menigatti","year":"2009","journal-title":"Mol Cancer"},{"key":"2026040200274608600_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/onc.2012.29","article-title":"Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer","volume":"32","author":"Su","year":"2013","journal-title":"Oncogene"},{"key":"2026040200274608600_bib31","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/ijc.32015","article-title":"Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation","volume":"144","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"key":"2026040200274608600_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.03.009","article-title":"Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)","volume":"143","author":"Eide","year":"2020","journal-title":"Lung Cancer"},{"key":"2026040200274608600_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026040200274608600_bib34","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026040200274608600_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdh011","article-title":"Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer","volume":"15","author":"Selvaggi","year":"2004","journal-title":"Ann Oncol"},{"key":"2026040200274608600_bib36","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"key":"2026040200274608600_bib37","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat Med"},{"key":"2026040200274608600_bib38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"key":"2026040200274608600_bib39","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"key":"2026040200274608600_bib40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov"},{"key":"2026040200274608600_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"issue":"17_suppl","key":"2026040200274608600_bib42","doi-asserted-by":"crossref","first-page":"LBA8511","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8511","article-title":"KROCUS: a phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC","volume":"42","author":"Gregorc","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2026040200274608600_bib43","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1200\/JCO.2024.42.16_suppl.8559","article-title":"Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: a phase 1b study","volume":"42","author":"Langer","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026040200274608600_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc1837","article-title":"Protein-tyrosine phosphatases and cancer","volume":"6","author":"Ostman","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2026040200274608600_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrm2039","article-title":"Protein tyrosine phosphatases: from genes, to function, to disease","volume":"7","author":"Tonks","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026040200274608600_bib46","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1158\/1078-0432.CCR-16-0934","article-title":"Molecular pathways: targeting protein tyrosine phosphatases in cancer","volume":"23","author":"Bollu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026040200274608600_bib47","doi-asserted-by":"crossref","first-page":"29503","DOI":"10.1074\/jbc.M202149200","article-title":"Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway","volume":"277","author":"Buschbeck","year":"2002","journal-title":"J Biol Chem"},{"key":"2026040200274608600_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12885-015-1012-8","article-title":"Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1\/2 signalling in prostate cancer cells","volume":"15","author":"Munkley","year":"2015","journal-title":"BMC Cancer"},{"key":"2026040200274608600_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molcel.2016.12.004","article-title":"A global analysis of the receptor tyrosine kinase-protein phosphatase interactome","volume":"65","author":"Yao","year":"2017","journal-title":"Mol Cell"},{"key":"2026040200274608600_bib50","doi-asserted-by":"crossref","first-page":"12249","DOI":"10.1074\/jbc.M608525200","article-title":"Inhibition of the extracellular signal-regulated kinase\/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells","volume":"282","author":"Lu","year":"2007","journal-title":"J Biol Chem"},{"key":"2026040200274608600_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature23274","article-title":"Prolonged Mek1\/2 suppression impairs the developmental potential of embryonic stem cells","volume":"548","author":"Choi","year":"2017","journal-title":"Nature"},{"key":"2026040200274608600_bib52","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"key":"2026040200274608600_bib53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2026040200274608600_bib54","doi-asserted-by":"crossref","first-page":"e202201466","DOI":"10.26508\/lsa.202201466","article-title":"Predictive data-driven modeling of C-terminal tyrosine function in the EGFR signaling network","volume":"6","author":"Gerritsen","year":"2023","journal-title":"Life Sci Alliance"},{"key":"2026040200274608600_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/1535-7163.MCT-23-0218","article-title":"MIG6 mediates adaptive and acquired resistance to ALK\/ROS1 fusion kinase inhibition through EGFR bypass signaling","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2026040200274608600_bib56","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1073\/pnas.1319551111","article-title":"Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer","volume":"111","author":"Lui","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0489\/3746769\/crc-25-0489.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/728\/3761974\/crc-25-0489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/728\/3761974\/crc-25-0489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:27:59Z","timestamp":1775104079000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/4\/728\/781786\/Constitutive-EGFR-Activation-Induced-by-PTPRR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0489","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31921691","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921745","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921733","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921754","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921742","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921730","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921751","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921739","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921727","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921715","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921748","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921736","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31921724","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8397896","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}